Infinity Pharma (NASDAQ:INFI) reported Q1 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $652 thousand versus the consensus...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Utilities, Consumer Goods and Telecoms sectors led shares higher while losses in the Basic...
Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) were up 12% yesterday after the FDA granted a Fast Track designation to the combo of IPI-549 plus Bristol Myers’...
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) incurred a loss of 20 cents per share in the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 19...
Infinity Pharmaceuticals, Inc. clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.
|Average||6.071 (+410.20% Upside)|
|No. of Analysts||7|